Eptinezumab
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Eptinezumab: From Migraine Prevention to Migraine with Brainstem Aura
One-Sentence Summary
Eptinezumab is an anti-CGRP (calcitonin gene-related peptide) monoclonal antibody; internationally it is approved almost exclusively for migraine prevention, though this database has no on-file record of an approved indication for this market. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura, with 0 registered clinical trials and 8 publications currently supporting this direction — evidence level L3.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in database (no approved-indication text on file; internationally eptinezumab's approved use is migraine prevention) |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L3 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data (original_moa) is marked as a data gap, and no original indication is recorded in this database. Based on the mechanistic rationale supplied with the prediction, eptinezumab is an anti-CGRP monoclonal antibody that works by neutralizing circulating CGRP ligand, thereby blocking pain transmission through the trigeminovascular system — the core mechanism underlying current migraine prevention therapy.
Migraine with brainstem aura is a specific migraine subtype whose aura symptoms are believed to be primarily driven by cortical spreading depression (CSD), a phenomenon whose relationship to the CGRP pathway is more indirect than that of headache pain itself. Historically, vasoconstrictive drugs such as triptans have raised caution in patients with brainstem-aura symptoms; CGRP monoclonal antibodies like eptinezumab do not show comparable vasoconstrictive activity, which is mechanistically reassuring.
That said, the current evidence base is inferential rather than confirmatory: no trial has directly validated eptinezumab in patients specifically diagnosed with migraine with brainstem aura. Supporting literature largely consists of post-hoc analyses of general migraine-with-aura populations, reviews of CGRP biology, and case reports — reasonable grounds for a research hypothesis, but not yet sufficient for a treatment claim in this subtype.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35302389 | 2022 | Post-hoc analysis of RCT | Cephalalgia | Post hoc subgroup analysis of PROMISE-1/2 evaluating efficacy and safety of eptinezumab in migraine patients with self-reported aura |
| 40229719 | 2025 | RCT (PACAP38, non-eptinezumab) | J Headache Pain | RCT showing PACAP38-induced migraine attacks occur independently of CGRP signaling — relevant context on CGRP-pathway boundaries |
| 35268319 | 2022 | Case report/Review | J Clin Med | Case reports and literature review on whether anti-CGRP mAbs (incl. eptinezumab) are effective at preventing migraine aura specifically |
| 30725283 | 2019 | Review | Handb Exp Pharmacol | Review of CGRP's central role in migraine pathophysiology and the trigeminovascular system |
| 32699706 | 2020 | Review | Cureus | Review of CGRP antagonists in episodic and chronic migraine management |
| 33550872 | 2021 | Review (different drug class) | Pain Management | Overview of new acute/preventive migraine therapies, including eptinezumab among others |
| 40341526 | 2025 | Review (genetic) | Headache | Case series of genetic migraine disorders responsive to CGRP antagonist therapy |
| 40191903 | 2025 | Case report | Rev Neurol | Chronic migraine with wearing-off effect successfully managed with eptinezumab after failure of two other CGRP mAbs |
Norway Market Information
No Norway market authorizations on record — eptinezumab is currently not marketed in this jurisdiction (0 licenses).
Safety Considerations
Please refer to the package insert for safety information.
(Note: key warnings, contraindications, and drug–drug interaction data are all currently unavailable in this database — flagged as a Blocking data gap, DG001. This must be resolved before any safety-stage evaluation.)
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical trial evidence directly supporting eptinezumab in migraine with brainstem aura, safety/label data is currently a blocking data gap, and the drug is not marketed in this jurisdiction. The mechanistic rationale is plausible but inferential, placing this candidate appropriately at the "Research Question" stage rather than one ready for regulatory or clinical action.
To proceed, the following is needed:
- TFDA/label warnings and contraindications (DG001, Blocking)
- Confirmed mechanism of action and approved-indication record for this market (DG002, High)
- Prospective or subgroup-specific trial data in patients with confirmed migraine-with-brainstem-aura (not just self-reported aura)
- Regulatory filing/market-entry status assessment given current "Not Marketed" status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.